Presente y futuro del tratamiento de segunda línea del cáncer de pulmón no microcítico

31 / 48

INSIGNA: ECOG/SWOG Advanced Non-squamous Trial wit
Pembrolizumab
 Primary Endpoint: OS
 Overall Objective: Determine which approach is of greatest
benefit in 1st line therapy of Non-Squamous NSCLC
Pembrolizumab
Induction Maintenance
2nd Line Treatment
Carbo/Pemetre
xed/
Pembrolizumab
Pembrolizumab
Pemetrexed/
Pembrolizumab
Carbo/Pemetrexed/
Pembrolizumab
Not Specified
Carbo/Pemetrexed
≥1% TPSpositive
Randomization
*
Arm B
1 st Line Treatment
Post-Progression
Advanced
on-squamous
NSCLC
PIs: H. Borghaei (ECOG) and A. Chiang (SWOG)